The special case of gene therapy pricing.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 25203033.
- Also identified by DOI 10.1038/nbt.3003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.
Medical subject headings
- Genetic Therapy